Sumitomo Pharma Co Ltd
TSE:4506
Operating Margin
Sumitomo Pharma Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
Sumitomo Pharma Co Ltd
TSE:4506
|
420.3B JPY |
7%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
777B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
378.3B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
214.6B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.6B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
170.3B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
206.3B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140.4B USD |
27%
|
Sumitomo Pharma Co Ltd
Glance View
In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Sumitomo Pharma Co Ltd's most recent financial statements, the company has Operating Margin of 7.5%.
You don't have any saved screeners yet